ReviewDrug discovery today. Technologies2014
Overcoming antifungal resistance.
Review in Drug discovery today. Technologies, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 114 citations in OpenAlex.
- Epidemiological Trends and Clinical Features ofJournal of Korean medical science · 2025Article
- Fungal immunization potentiates CD4Frontiers in immunology · 2025Article
- Review
- Harnessing Machine Learning to Uncover Hidden Patterns in Azole-Resistant CYP51/ERG11 Proteins.Microorganisms · 2024Article
- Improving antifungal stewardship in dermatology in an era of emerging dermatophyte resistance.JAAD international · 2024Article
- New insides into chimeric and hybrid azines derivatives with antifungal activity.Future medicinal chemistry · 2024Review
- Antifungal resistance and stewardship: a knowledge, attitudes and practices survey among pharmacy students at the University of Zambia; findings and implications.JAC-antimicrobial resistance · 2023Article
- An update on the global treatment of invasive fungal infections.Future microbiology · 2023Review
- Species distribution and susceptibility profiles of oral candidiasis in hematological malignancy and solid tumor patients.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2023Article
- Antifungal Activity of Bulgarian Rose Damascena Oil against Vaginitis-Causing Opportunistic Fungi.Evidence-based complementary and alternative medicine : eCAM · 2023Article
- Potent antifungal properties of gallic acid inBiotechnologia · 2023Article
- Design of a multi-epitope vaccine against the pathogenic fungi Candida tropicalis using an in silico approach.Journal, genetic engineering & biotechnology · 2022Article
- Photoinactivation of Catalase Sensitizes Candida albicans and Candida auris to ROS-Producing Agents and Immune Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Sanguinarine, Isolated FromFrontiers in microbiology · 2022Article
- Transcriptomic studies on Purpureocillium lilacinum reveal molecular mechanisms of response to fluconazole and itraconazole.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2021Article
- Drug Repurposing in Medical Mycology: Identification of Compounds as Potential Antifungals to Overcome the Emergence of Multidrug-Resistant Fungi.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Fighting Antibiotic Resistance in Hospital-Acquired Infections: Current State and Emerging Technologies in Disease Prevention, Diagnostics and Therapy.Frontiers in microbiology · 2021Review
- Antifungal Susceptibility Testing ofACS infectious diseases · 2020Article
- Current Insights on Antifungal Therapy: Novel Nanotechnology Approaches for Drug Delivery Systems and New Drugs from Natural Sources.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Terpinen-4-ol and nystatin co-loaded precursor of liquid crystalline system for topical treatment of oral candidiasis.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Fungal infections have become one of the major causes of morbidity and mortality in immunocompromised patients. Despite increased awareness and improved treatment strategies, the frequent development of resistance to the antifungal drugs used in clinical settings contributes to the increasing toll of mycoses. Although a natural phenomenon, antifungal drug resistance can compromise advances in the development of effective diagnostic techniques and novel antifungals. In this review, we will discuss the advent of cellular-micro- arrays, microfluidics, genomics, proteomics and other state-of-the art technologies in conquering antifungal drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.